Tenofovir (all routes except local)

Neonatal death (< 28 days of life)

id	Study   Auto Floridia, 2018Pintye, 2017Zash (Controls exposed to other treatments), 2017Fowler, 2016	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimester	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedsiblingwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S5134 R13389	Floridia, 2018	Neonatal death (NOS)	during pregnancy (anytime or not specified)	cohort	exposed to other treatment, sick	Adjustment: No Control group: Abacavir/Lamivudine-based Exposed group: TDF/emtricitabine-based Indication: HIV	0.63 [0.15;2.68]	5/586   3/224	8	586		ref
S5153 R13441	Pintye, 2017	Neonatal death (within 3 days following live birth)	during pregnancy (anytime or not specified)	prospective cohort	exposed to other treatment, sick	Adjustment: Yes Control group: zidovudine/lamivudine-based Exposed group: TDF/lamivudine-based Indication: PrEP	0.68 [0.17;2.78]	3/-   4/-	7	-		ref
S5258 R13595	Zash (Controls exposed to other treatments), 2017	Neonatal death (< 28days)	during pregnancy (anytime or not specified)	retrospective cohort	exposed to other treatment, sick	Adjustment: No Control group: zidovudine/lamivudine-based Exposed group: TDF (mix or unspecified regimens) Indication: HIV	0.58 [0.37;0.90] C	46/3,463   35/1,532	81	3,463		ref
S5131 R13343	Fowler, 2016	Infant deaths through week 1	2nd and/or 3rd trimester	randomized controlled trial	exposed to other treatment, sick	Adjustment: Randomisation Control group: zidovudine/lamivudine/lopinavir–ritonavir Exposed group: TDF/emtricitabine/lopinavir–ritonavir Indication: HIV	7.91 [1.80;34.88] C	15/341   2/346	17	341		ref
					Total	4 studies	1.07 [0.36;3.16]		113	4,390
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis

Publication bias and p-hacking diagnosis

Sub-groups analysis using all included studies

excluded